Kohli R S, Lahiri A, Raftery E B
J Cardiovasc Pharmacol. 1986;8 Suppl 11:S148-53. doi: 10.1097/00005344-198511001-00027.
The efficacy of once-daily bisoprolol (10 mg) and atenolol (100 mg) was assessed in 19 patients with stable angina, using a double-blind randomized crossover protocol and computer-assisted treadmill exercise testing with continuous monitoring of leads CM5 and CC5, the test being carried out 22-24 h after the last dose. The mean +/- SEM exercise time on placebo was 6.5 +/- 0.4 min increasing to 7.8 +/- 0.5 min on bisoprolol (p less than 0.02) and 8.6 +/- 0.6 min on atenolol (p less than 0.001). The increase in exercise time with atenolol was significantly greater than with bisoprolol (p less than 0.02). The time to 1 mm ST-depression in CM5 and CC5 was also prolonged significantly with both drugs compared to placebo, but with no difference between the two active treatments. The mean resting heart rate of 84 +/- 4 beats/min decreased to 63 +/- 2 beats/min on bisoprolol (p less than 0.001) and 64 +/- 2 beats/min on atenolol (p less than 0.001) with a significant decrease in the peak exercise heart rate seen with both drugs (p less than 0.001). The peak rate-pressure product (beats/min X mm Hg X 10(-2)) was 175 +/- 8 after placebo, 146 +/- 7 (p less than 0.001) after bisoprolol and 149 +/- 5 (p less than 0.01) after atenolol. One patient was withdrawn because he suffered a myocardial infarction. After completion of the crossover phase, 18 of the patients were prescribed bisoprolol 10 mg once a day for 6 weeks. Twelve patients were treated for 12 weeks. An exercise test was performed at the end of each 6-week period. The effects of bisoprolol on all parameters were maintained. In conclusion, bisoprolol is an effective antianginal agent, comparable in efficacy and duration of action with atenolol, and is suitable for once daily administration.
采用双盲随机交叉试验方案，并通过计算机辅助的平板运动试验持续监测CM5和CC5导联，对19例稳定型心绞痛患者评估了每日一次服用比索洛尔（10毫克）和阿替洛尔（100毫克）的疗效，试验在最后一剂药物服用后22 - 24小时进行。安慰剂组的平均运动时间±标准误为6.5±0.4分钟，服用比索洛尔后增加至7.8±0.5分钟（p<0.02），服用阿替洛尔后为8.6±0.6分钟（p<0.001）。阿替洛尔使运动时间的增加显著大于比索洛尔（p<0.02）。与安慰剂相比，两种药物使CM5和CC5导联中ST段压低1毫米的时间也显著延长，但两种活性药物之间无差异。平均静息心率84±4次/分钟，服用比索洛尔后降至63±2次/分钟（p<0.001），服用阿替洛尔后为64±2次/分钟（p<0.001），两种药物均使运动高峰心率显著降低（p<0.001）。安慰剂组后的峰值心率血压乘积（次/分钟×毫米汞柱×10⁻²）为175±8，比索洛尔组后为146±7（p<0.001），阿替洛尔组后为149±5（p<0.01）。一名患者因发生心肌梗死退出试验。交叉阶段结束后，18例患者每日服用一次10毫克比索洛尔，持续6周。12例患者接受治疗12周。在每6周结束时进行一次运动试验。比索洛尔对所有参数的作用均得以维持。总之，比索洛尔是一种有效的抗心绞痛药物，在疗效和作用持续时间上与阿替洛尔相当，适合每日一次给药。
